RPRX Stock Analysis — Royalty Pharma
Sector: Healthcare
AI Verdict
RPRX is cheap for the growth on offer at 10.3x forward earnings, but you're betting that the royalty model delivers the huge jump in profits analysts expect.
Competitive Moat
Royalty Pharma acquires pharmaceutical royalty streams, giving it access to a diversified portfolio of drug revenues without the risk and cost of R&D. Its scale and deep industry relationships allow it to source exclusive deals that smaller players can't match, creating a durable sourcing advantage.
Summary
A huge expected jump in earnings is driving RPRX's forward P/E down to 10.3x, far below the healthcare sector median.
Where It Stands
RPRX trades at 10.3x next year's earnings versus the healthcare median of 22x, with analyst consensus calling for 310.6% EPS growth — a rare combination of low price and explosive growth expectations.
Key Metrics
- Trailing P/E: 42.3x
- Forward P/E: 10.3x
- PEG Ratio: 0.14
- Earnings Growth: +3.1%
- Revenue Growth: +0.1%
- Dividend Yield: 0.02%
- 52-Week High: $58.84
- 52-Week Low: $34.08
Analyst Consensus
14 Buy · 2 Hold · 0 Sell (16 analysts)
Bull Case
With forward EPS growth forecast at 310.6%, the 10.3x forward P/E is cheap for the growth you're getting if the royalty pipeline delivers as expected.
Bear Case
If the 310.6% EPS growth fails to materialize, the stock could quickly revert toward its trailing P/E of 42.3x, implying a sharp valuation reset.
Catalyst to Watch
Watch for actual reported EPS in the next quarterly results — a miss versus the triple-digit growth expectation would likely trigger a major rerating.